Press Releases

Feb 6, 2019

FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

- First medicine approved in the U.S. specifically for the treatment of aTTP, a rare blood-clotting disorder
Jan 23, 2019

FDA approves use of 0.5 mL dose of Fluzone® Quadrivalent (influenza vaccine) in children as young as 6 months of age

- The 0.5 mL dose is now approved for use in children 6 months through 35 months of age
Jan 17, 2019

FDA advisory committee votes on Zynquista™ (sotagliflozin) as treatment for adults with type 1 diabetes
Jan 14, 2019

FDA Approves Expanded Use of Adacel® (Tdap) Vaccine for Repeat Vaccination

* First and only vaccine approved in the U.S. for repeat vaccination 8 years or more after the first vaccination to help protect against tetanus, diphtheria and pertussis, offering flexibility for health care providers to help manage their immunization schedules(2)
Jan 9, 2019

New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi® (caplacizumab) for rare blood clotting disorder

-HERCULES Phase 3 trial met its primary endpoint, demonstrating that treatment with Cablivi resulted in a significantly faster time to platelet count response in patients with acquired thrombotic thrombocytopenic purpura (aTTP) when administered in conjunction with plasma exchange and immunosuppression

Show per page